- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04344210
Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus
Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial
INTRODUCTION In critical situations, such as the current COVID 19 pandemic, themes of fear, uncertainty and stigmatization are common and constitute barriers to appropriate medical and mental health interventions. These challenges, when faced by those who live with a chronic disease, such as diabetes mellitus (DM), can negatively influence quality of life and adherence to treatment, compromising the control of the disease.
OBJECTIVES The present study aims to investigate the effectiveness of a tele-intervention during the COVID-19 pandemic in improving glycemic control, lipid profile, blood pressure levels and parameters of medication adherence, mental well-being and sleep quality in patients with type 1 DM and type 2 DM.
METHODS A randomized clinical trial will be carried out with patients with a previous diagnosis of type 1 DM and type 2 DM, who are registered at the Hospital de Clínicas de Porto Alegre (HCPA). Inclusion criteria will be age greater than or equal to 18 years, collection of HbA1c in the HCPA laboratory in January, February or March 2020 and availability to receive weekly phone calls. Patients will be randomized, stratified by type of diabetes, in two groups: G1: participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the social distancing period ; G2: participants will receive the usual care. The primary outcome assessed will be the variation in HbA1c levels comparatively between groups, with or without a tele-guided strategy, after four months of social distancing (or as long as the recommendation of social distancing measures remains). Secondary outcomes will include experiencing confirmation of COVID-19 infection, variation in lipid profile, blood pressure levels and variation in parameters of emotional distress related to diabetes, eating disorders, medication adherence, symptoms minor psychiatric disorders and altered sleep patterns, which will be evaluated with specific and validated scales. According to the sample calculation, 150 patients will be included in the study (92 with type 2 DM and 58 with type 1 DM). Analysis by intention to treat will be performed separately for patients with type 1 DM and with type 2 DM.
SCHEDULE The proposed experiment will start immediately after approval of this project by the research ethics committee. The duration of the proposed intervention is 4 months (or as long as the recommendation of social distancing measures remains. This means that the study may be completed before or after that period, based on national recommendations for social distancing in Brazil), with a data analysis plan and publication of the results until September 2020.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brasile, 90620-170
- Hospital de Clínicas de Porto Alegre
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Type 1 diabetes mellitus or type 2 diabetes mellitus;
- Age greater than or equal to 18 years;
- HbA1c assessed in January, February or March 2020;
- Availability to receive weekly phone calls
Exclusion Criteria:
- Any severe cognitive limitation that prevents the necessary interaction to carry out this study (advanced dementia, deafness, dysarthria, aphasia);
- Do not present a telephone record in an electronic medical record;
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Tele-Intervention
Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
|
Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
|
|
Nessun intervento: Usual Care
Participants will receive the usual care
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Variation in HbA1c levels
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
|
Variation in HbA1c levels comparatively between groups after the period of social distancing measures.
|
4 months (or as long as the recommendation of social distancing measures remains)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
COVID-19 infection
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
|
Confirmation of coronavirus infection by rapid test
|
4 months (or as long as the recommendation of social distancing measures remains)
|
|
Variation in lipid profile
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
|
Comparison of the lipid profile of the last year with the lipid profile after the intervention between the groups.
|
4 months (or as long as the recommendation of social distancing measures remains)
|
|
Variation in blood pressure levels
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
|
Comparison of the blood pressure level of the last consultation with the pressure after the intervention between the groups.
|
4 months (or as long as the recommendation of social distancing measures remains)
|
|
Comparison of emotional distress associated with the routine of living with diabetes after intervention between groups
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
|
Evaluation of emotional distress associated with the routine of living with diabetes - B-PAID (Brazilian Problem Areas In Diabetes Scale)
|
4 months (or as long as the recommendation of social distancing measures remains)
|
|
Comparison of eating disorders between groups
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
|
Evaluation of eating disorders - EAT - 26 SCALE (Teste de Atitudes Alimentares)
|
4 months (or as long as the recommendation of social distancing measures remains)
|
|
Comparison of adherence to the proposed clinical treatment between groups
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
|
Evaluation of adherence to the proposed clinical treatment - SCI R (Self-Care Inventory - revised)
|
4 months (or as long as the recommendation of social distancing measures remains)
|
|
Comparison of minor psychiatric disorders between groups
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
|
Evaluation of minor psychiatric disorders - SRQ 20 (Self Report Questionnaire)
|
4 months (or as long as the recommendation of social distancing measures remains)
|
|
Comparison of sleep pattern changes between groups
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
|
Evaluation of sleep pattern changes - MSQ (Mini Sleep Questionnaire)
|
4 months (or as long as the recommendation of social distancing measures remains)
|
Collaboratori e investigatori
Pubblicazioni e link utili
Pubblicazioni generali
- Alessi J, Becker AS, Amaral B, de Oliveira GB, Franco DW, Knijnik CP, Kobe GL, de Brito A, de Carvalho TR, Telo GH, Schaan BD, Telo GH. Type 1 diabetes and the challenges of emotional support in crisis situations: results from a feasibility study of a multidisciplinary teleintervention. Sci Rep. 2022 May 20;12(1):8526. doi: 10.1038/s41598-022-12227-z.
- Alessi J, Becker AS, Amaral B, de Oliveira GB, Franco DW, Knijnik CP, Kobe GL, de Brito A, de Carvalho TR, Telo GH, Schaan BD, Telo GH. Type 1 diabetes and the challenges of emotional support in crisis situations: results from a randomized clinical trial of a multidisciplinary teleintervention. Sci Rep. 2022 Feb 23;12(1):3086. doi: 10.1038/s41598-022-07005-w.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Disturbi del metabolismo del glucosio
- Malattie metaboliche
- Infezioni da coronavirus
- Infezioni da Coronaviridae
- Infezioni da Nidovirus
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni delle vie respiratorie
- Malattie delle vie respiratorie
- Malattie del sistema immunitario
- Malattie autoimmuni
- Polmonite, virale
- Polmonite
- Malattie polmonari
- Malattie del sistema endocrino
- COVID-19
- Diabete mellito
- Diabete mellito, tipo 2
- Diabete mellito, tipo 1
Altri numeri di identificazione dello studio
- 2020241093
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- CODICE_ANALITICO
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .